← All indications
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Subtype terms (4)
More specific conditions that are subtypes of Colorectal Neoplasms in the MeSH hierarchy.
- Adenomatous Polyposis Coli
40 drugs (19 approved, 21 experimental)
- Colonic Neoplasms
473 drugs (211 approved, 262 experimental)
- Colorectal Neoplasms, Hereditary Nonpolyposis
24 drugs (19 approved, 5 experimental)
- Rectal Neoplasms
270 drugs (124 approved, 146 experimental)
Drugs by status
Approved for this indication (17)
Phase 4 trials (64)
- isoflurane
- iron
- darbepoetin alfa
- l-glutamine
- dexamethasone
- propofol
- ferrous sulfate
- mosapride
- epinephrine
- sennosides a&b
- gadoxetate disodium
- piritramide
- desflurane
- barium sulphate
- esomeprazole
- ferric derisomaltose
- celecoxib
- calcium hydroxide
- amphotericin b
- iron dextran
- rc48-adc
- tobramycin
- ferric carboxymaltose
- oxaliplatin
- polyethylene glycol
- pembrolizumab
- saccharomyces boulardii
- mineral trioxide
- insulin human
- gadobenate
- +34 more
Phase 3 trials (176)
- sunitinib
- docetaxel
- sacituzumab govitecan
- chidamide
- carboplatin
- water
- cadonilimab
- propranolol
- titanium
- melphalan
- human choriogonadotropin alfa
- encorafenib
- pyridoxine
- escherichia coli nissle 1917
- binimetinib
- jianpi huatan
- calcium
- autologous microbiome
- oteracil
- ropivacaine
- cisplatin
- sotorasib
- minocycline
- dalteparin
- calcium carbonate
- lefitolimod
- bp102
- mk-4280
- eflornithine
- gefitinib
- +146 more
Phase 2 trials (716)
- becatecarin
- phosphatidylcholine
- conatumumab
- simurosertib
- 105ad7
- futibatinib
- oncos-102
- qbeco
- xmab20717
- rucaparib
- yyb101
- gm103
- alpelisib
- mrna-engineered t cells targeting mutant transforming growth factor beta receptor type ii
- denosumab
- autologous t cells
- seribantumab
- bms-986340
- trimetrexate
- mgd007
- topotecan
- iab22m2c
- hcb101
- vicriviroc
- gsk4418959
- rexin-g
- autologous cd133+ stem cells
- leac-102
- fostamatinib
- vorinostat
- +686 more
Phase 1 trials (467)
- il13r alpha peptide
- rmc-6291
- budigalimab
- im96 car-t cells
- [68ga]ga-nns309
- bi 1701963
- bbo-10203
- tbio-4101
- merestinib
- ocv-103
- re-activated t cells
- egfrbi armed atc infusions
- oatd-02
- nkg2dl-targetting chimeric antigen receptor-grafted gamma delta t cell
- tils and car-tils targeting her2, mesothelin, psca, muc1, lewis-y, gpc3, axl, egfr, claudin18.2/6, ror1, gd1, or b7-h3
- abbv-514
- py159
- kf-0210
- bi 765063
- cantuzumab ravtansine
- ino-9012
- ivx037
- suramin
- bavituximab
- resveratrol
- pepticrad-1
- 68ga-sgc8
- car t cells
- janx008
- y90 monoclonal antibody hu3s193
- +437 more
Other trials (76)
- bovine lactoferrin
- quercetin
- bisacodyl
- oryza sativa
- amioca starch
- allogeneic bone marrow
- atracurium
- remifentanil
- panthenol
- heroin
- ef5
- ramosetron
- indigotindisulfonate sodium
- kanglaite
- syh2051
- autologous dendritic cells electroporated with wt1 mrna
- camelina seed oil
- ethanol
- magnesium glycinate
- ketamine
- rocuronium
- sodium sulfate
- fapi-46
- pegulicianine
- soybean oil
- Lactobacillus johnsonii N6.2
- her-2-neu, cea peptides, gm-csf, montanide isa-51 vaccine
- ibuprofen
- 68ga-nota-gpa33
- sys6010
- +46 more
Organizations
Organization Involved with Phase 4 Indications (62)
- Department of Veteran Affairs
- Genentech
- Tomas Bata Hospital Zlin
- Kaohsiung Medical University
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Federal University of Minas Gerais
- University of Helsinki
- University of Barcelona
- Erasmus University Rotterdam
- Charles University
- University of Gothenburg
- Zhejiang University
- University of Limoges
- University of Nottingham
- Humboldt University
- Klinikum Aschaffenburg-Alzenau
- King Saud University
- University of Ostrava
- Palacky University
- Hospital Novy Jicin
- Tel Aviv University
- Nutricia
- University of Lyon
- RUMC
- Vifor Inc.
- National Institute for Health Research, United Kingdom
- Johannes Gutenburg University
- Institut de Recherche Clinique sur les Cancers et le Sang
- Fudan University
- Orivas
- +32 more
Organization Involved with Phase 3 Indications (290)
- Cancer Research UK
- Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
- Biothera
- University of St-Luc
- Stand Up To Cancer
- Prologue Research International
- Hospital Avicenne
- AIG Hyderabad india
- Iwate Medical University
- Koningin Wilhelmina Fonds
- Hokkaido University
- SCRI Development Innovations
- Daiichi Sankyo
- Utrecht University
- Northwell Health
- Mayo Clinic
- National Hospital Organization Kyoto Medical Center
- Osaka University
- INDOX Cancer Research Network
- Wuhan University
- Government of Singapore
- Hengrui Therapeutics, Inc.
- Multicenter Clinical Study Group of Osaka
- Immunovative Therapies
- Mast Therapeutics
- Chinese Medical University
- Istituto Nazionale per lo Studio e la Cura dei Tumori
- Arbeitsgemeinschaft fur Internistische Onkologie (AIO)
- Southwest Oncology Group
- Chonnam National University
- +260 more
Organization Involved with Phase 2 Indications (500)
- Norwegian Cancer Society
- LabCorp
- Hospital General Yague
- SOFAR S.p.A.
- University of the Philippines
- British Columbia Cancer Agency
- Western Hospital, Footscray, Victoria. Australia
- Galectin Therapeutics Inc.
- Grupo Oncologico Cooperativo del Sur
- Celleron Therapeutics Ltd.
- National Cancer Institute, Italy
- University of Tuebingen
- Universitat de Vic
- University of Texas, San Antonio
- INCLIVA
- The Rogosin Institute
- University of Bern
- Effector Therapeutics
- Unidad Integral de Investigación en Oncología S.L.
- Catalysis SL
- Cancer Treatment Centers of America
- Menarini Group
- Esslingen University
- EPS Corporation
- Istituto Clinico Humanitas - Rozzano (MI), Italy
- Actuate Therapeutics Inc.
- ClinAssess GmbH
- Western General Hospital, Australia
- University of Athens
- Puma Biotechnology, Inc.
- +470 more
Organization Involved with Phase 1 Indications (84)
- Research Institute of Fundamental and Clinical Immunology
- Besins Healthcare
- Merus Labs
- PharmaEngine
- Targovax ASA
- Iuliu Hatieganu University of Medicine and Pharmacy
- Epimmune
- GSO Global Clinical Research BV
- Vaccinex Inc.
- Pierrel Research
- Dynavax Technologies Corporation
- ICON
- German Cancer Research Center
- Chiltern International
- 4Clinics
- Celldex Therapeutics
- Tolero Pharmaceuticals
- Fennec Pharma
- University of Indonesia
- OncoGenex Technologies
- Central Georgia Cancer Care
- Q2 solutions
- Isarna Therapeutics GmbH
- National University of Ireland
- Aduro BioTech
- Bionomics Limited
- Oakland University
- Celyad
- Aventis
- Navidea Biopharmaceuticals
- +54 more
Organization Involved with Other Experimental Indications (41)
- Biokinetic Europe Ltd
- Gottfried und Julia Bangerter-Rhyner Foundation, Switzerland
- General Electric
- Saskatoon Health Region
- University of New Mexico
- Immunotec Inc.
- Maria Isabel Toulson Davisson Correia
- Shanghai University of Traditional Chinese Medicine
- Korea Institute of Oriental Medicine
- Kangbuk Samsung Hospital
- Korea Ginseng Corporation
- Medtronic
- Colorado State University
- Mansoura University
- Nuovo Regina Margherita Hospital
- Nanchong Central Hospital
- University of Vermont
- Pusan National University
- Hospital Aleman
- Federal University of Santa Catarina
- Iowa Digestive Disease Center
- York University
- New Mexico Cancer Care Alliance
- Cairo University
- Poudre Valley Health System
- National University of Malaysia
- Nasser Institute For Research and Treatment
- Centro de Pesquisas Oncológicas de Florianópolis
- Mercy Medical Center, Des Moines, Iowa
- Legacy Health System
- +11 more